Motor changes in presymptomatic Huntington disease gene carriers

Archives of Neurology

Volumn 53, Issue 6, 1996, Pages 487-492

  Siemers, Eric ^a   Foroud, Tatiana ^a   Bill, Daniel J ^a   Sorbel, Jeffrey ^a   Norton Jr , James A ^a   Hodes, M E ^a   Niebler, Gwendolyn ^a   Conneally, P Michael ^a   Christian, Joe C ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ALLELISM; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HETEROZYGOTE; HUMAN; HUMAN CELL; HUMAN TISSUE; HUNTINGTON CHOREA; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REACTION TIME; RISK ASSESSMENT;

EID: 0029977215     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.1996.00550060029011     Document Type: Article

References (21)

1. Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 1993;72:971-983.
2. Folstein SE. Huntington's Disease: A Disorder of Families. Baltimore, Md: Johns Hopkins University Press; 1989.
3. Farrer LA, Conneally PM. A genetic model for age at onset in Huntington disease. Am J Hum Genet. 1985;37:350-357.
4. Burch PRJ. Genetic and pathogenetic implications of the age incidence of Huntington's chorea. Adv Neurol. 1973;1:179-190.
5. Foroud T, Siemers E, Kleindorfer D, et al. Cognitive scores of Huntington disease gene carriers as compared to non-gene carriers. Ann Neurol. 1995;37:657-664.
6. Giordani B, Berent S, Boivin MJ, et al. Longitudinal neuropsychological and genetic linkage analysis of persons at risk for Huntington's disease. Arch Neurol. 1995;552:59-64.
7. Folstein SE, Jensen B, Leigh RJ, Folstein MF, The measurement of abnormal movement: methods developed for Huntington's disease. Neurobehav Toxicol Teratol. 1983;5:605-609.
8. Penny JB, Young BM, Shoulson I, et al. Huntington's disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals. Mov Disord. 1990;5:93-99.
9. Andrew SE, Goldberg YP, Kremer B, et al. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat Genet. 1993;4:398-403.
10. Snell RG, MacMillan JC, Cheadle JP, et al. Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. Nat Genet 1993;4:393-397.
11. Hochschild R. Improving the precision of biological age determinations, II: automatic human tests, age norms and variability. Exp Gerontol. 1989;24:301-316.
12. Winer BJ, Brown DR, Michels KM. Statistical Principles in Experimental Design. 3rd ed. New York, NY: McGraw-Hill International Book Co; 1991.
13. Aylward EH, Brandt J, Codori AM, et al. Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at-risk persons. Neurology. 1994;44:823-828.
14. Grafton ST, Mazziotta JC, Pahl JJ, et al. A comparison of neurological, metabolic, structural, and genetic evaluations in persons at risk for Huntington's disease. Ann Neurol. 1990;28:614-621.
15. Rothlind JC, Brandt J, Zee D, et al. Unimpaired verbal memory and oculomotor control in asymptomatic adults with the genetic marker for Huntington's disease. Arch Neurol. 1993;50:799-802.
16. Weeks RA, Harding AE, Brooks DJ, PET demonstrates a parallel loss of D1 and D2 dopamine receptors in asymptomatic gene carriers of Huntington's disease. Neurology. 1995;45(suppl 4):A220. Abstract.
17. Kuwert T, Noth J, Scholz D, et al. Comparison of somatosensory evoked potentials with striatal glucose consumption measured by positron emission tomography in the early diagnosis of Huntington's disease. Mov Disord. 1993;8:98-106.
18. Young AB, Penney JB, Starosta-Rubinstein S, et al. Normal caudate glucose metabolism in persons at risk for Huntington's disease. Arch Neurol. 1987; 44:254-257.
19. Young AB, Shoulson I, Penney JB, et al. Huntington's disease in Venezuela: neurologic features and functional decline. Neurology. 1986;36:244-249.
20. Grafton ST, Mazziotta JC, Pahl JJ, et al. Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease. Arch Neurol. 1992;49:1161-1167.
21. Kieburtz K, MacDonald M. Shin C, et al. Trinucleotide repeat length and progression of illness in Huntington's disease. J Med Genet. 1994;31:872-874.